How RA Capital Cashes in on Private Deals

The little known life sciences hedge fund firm is a major investor in Covid-19 vaccine developer Novavax.


Shares of Novavax are on the move again.

The biotechnology company and vaccine developer, whose Covid-19 vaccine candidate is in various clinical trials and is being tested in South Africa and the U.K., was up nearly 7 percent on Monday, closing at $221.50.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.